Table 1. TLR agonists approved by FDA for use in humans against cancer and cancer-related conditions.

Agent	Main target(s)	Indications
Bacillus Calmette-Guérin	TLR2/TLR4	Superficial transitional cell carcinoma of the bladder
Monophosphoryl lipid A*	TLR2/TLR4	Adjuvant to Cervarix® for the prophylaxis of HPV-associated cervical cancer
Imiquimod	TLR7	Actinic keratosis, basal cell carcinoma, genital and perianal warts

Abbreviations: HPV, human papillomavirus. *combined with aluminum salts (AS04).